Artesunate Improves Venetoclax plus Cytarabine AML Cell Targeting by Regulating the Noxa/Bim/Mcl-1/P-Chk1 Axis

0
143
The authors provided a new triple combination for AML treatment by targeting the Noxa/myeloid cell leukemia-1 (Mcl-1)/B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim) axis to reverse Mcl-1/p-checkpoint kinase 1 (Chk1) resistance of cytarabine therapy.
[Cell Death & Disease]
Full Article